Generic placeholder image

Current Pharmaceutical Analysis

Author(s): Jia-jia Zou, Lin Yang, Xiao-li Xu, Yan Li and Dan He*

DOI: 10.2174/0115734129250659230929105800

DownloadDownload PDF Flyer Cite As
Method Validation and Monitoring of N-nitrosodimethylamine in Metformin Hydrochloride Products in China by GC-MS/MS

Page: [759 - 766] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background  N-nitrosodimethylamine (NDMA) are a sort of genotoxic impurities (GTIs) having strong carcinogenic effects and obvious hepatotoxicity. To monitor the NDMA content of metformin hydrochloride sustained-release tablets and enteric capsules in China from 2018 to 2022, a GC-MS/MS method was established and validated.

Materials and Methods: The chromatographic column was Agilent VF-WAXms capillary column (30 m×0.25 mm, 0.25 μm). The GC-MS/MS method was equipped with multiple reaction monitoring (MRM) modes. To assess the quantity of NDMA, the molecular ion at mass-tocharge (m/z) of 74-44 was monitored under the 6 V collision energy, and to assess the quality of NDMA monitoring, the molecular ions at m/z 74-42 were determined. A total of 143 batches of metformin hydrochloride-finished products from 35 enterprises were determined by this method.

Results: The linear range of the method was 0.25 ~ 50.00 ng/mL, r = 0.9998, S/N > 10, and the limit of detection and quantitation were 0.06 ng/mL and 0.21 ng/mL, respectively. The average recovery was 98.62%, and the RSD was 4.31%. All batches of enteric capsules met the requirements; 38.21% of the 123 batches sustained-release tablets still exceeded the acceptable daily intake.

Conclusion: The presented method is sensitive, accurate, precise, and available for both enteric capsules and sustained-release tablets of metformin hydrochloride, which can provide a reference for their quality control. The over-limit phenomenon of NDMA in metformin hydrochloride products poses new challenges and requirements for both the State Drug Administration and enterprises.

Graphical Abstract

[1]
Thresher, A.; Foster, R.; Ponting, D.J.; Stalford, S.A.; Tennant, R.E.; Thomas, R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul. Toxicol. Pharmacol., 2020, 116, 104749.
[http://dx.doi.org/10.1016/j.yrtph.2020.104749] [PMID: 32777431]
[2]
Jacobsen, N.R.; Pojana, G.; White, P.; Møller, P.; Cohn, C.A.; Smith Korsholm, K.; Vogel, U.; Marcomini, A.; Loft, S.; Wallin, H. Genotoxicity, cytotoxicity, and reactive oxygen species induced by single‐walled carbon nanotubes and C 60 fullerenes in the FE1‐Muta™Mouse lung epithelial cells. Environ. Mol. Mutagen., 2008, 49(6), 476-487.
[http://dx.doi.org/10.1002/em.20406] [PMID: 18618583]
[3]
Jacobsonkram, D.; McGovern, T. Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev., 2007, 59(1), 38-42.
[http://dx.doi.org/10.1016/j.addr.2006.10.007] [PMID: 17188779]
[4]
Adamson, R.H.; Chabner, B.A. The finding of n-nitrosodimethylamine in common medicines. Oncologist, 2020, 25(6), 460-462.
[http://dx.doi.org/10.1634/theoncologist.2020-0142] [PMID: 32267983]
[5]
Magee, P.N. Toxicity of nitrosamines: Their possible human health hazards. Food Cosmet. Toxicol., 1971, 9(2), 207-218.
[http://dx.doi.org/10.1016/0015-6264(71)90306-3] [PMID: 4997817]
[6]
Lewis, D.F.V.; Brantom, P.G.; Ioannides, C.; Walker, R.; Parke, D.V. Nitrosamine carcinogenesis: Rodent assays, quantitative structure-activity relationships, and human risk assessment. Drug Metab. Rev., 1997, 29(4), 1055-1078.
[http://dx.doi.org/10.3109/03602539709002243] [PMID: 9421685]
[7]
De Palma, R.; Patel, V.; Florian, J.; Keire, D.; Selaya, D.; Strauss, D.G.; Rouse, R.; Matta, M.K. A bioanalytical method for quantification of N-nitrosodimethylamine (NDMA) in human plasma and urine with different meals and following administration of ranitidine. J. Pharm. Sci., 2023, 112(5), 1315-1323.
[http://dx.doi.org/10.1016/j.xphs.2023.01.026] [PMID: 36736776]
[8]
Joung, K.I.; Hwang, J.E.; Oh, I.S.; Cho, S.; Shin, J.Y. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea. Sci. Rep., 2022, 12(1), 22396.
[http://dx.doi.org/10.1038/s41598-022-26691-0] [PMID: 36575247]
[9]
Bharate, S.S. Critical analysis of drug product recalls due to nitrosamine impurities. J. Med. Chem., 2021, 64(6), 2923-2936.
[http://dx.doi.org/10.1021/acs.jmedchem.0c02120] [PMID: 33706513]
[10]
Lim, H.H.; Oh, Y.S.; Shin, H.S. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography–tandem mass spectrometry. J. Pharm. Biomed. Anal., 2020, 189, 113460.
[http://dx.doi.org/10.1016/j.jpba.2020.113460] [PMID: 32663759]
[11]
Yoon, H.J.; Kim, J.H.; Seo, G.H.; Park, H. Risk of cancer following the use of n-nitrosodimethylamine (NDMA) contaminated ranitidine products: A nationwide cohort study in south korea. J. Clin. Med., 2021, 10(1), 153.
[http://dx.doi.org/10.3390/jcm10010153] [PMID: 33466237]
[12]
Sánchez, D.I.; González-Fernández, B.; San-Miguel, B.; de Urbina, J.O.; Crespo, I.; González-Gallego, J.; Tuñón, M.J. Melatonin prevents deregulation of the sphingosine kinase/sphingosine 1-phosphate signaling pathway in a mouse model of diethylnitrosamine-induced hepatocellular carcinoma. J. Pineal Res., 2017, 62(1), e12369.
[http://dx.doi.org/10.1111/jpi.12369] [PMID: 27696512]
[13]
Sörgel, F.; Kinzig, M.; Abdel-Tawab, M.; Bidmon, C.; Schreiber, A.; Ermel, S.; Wohlfart, J.; Besa, A.; Scherf-Clavel, O.; Holzgrabe, U. The contamination of valsartan and other sartans, part 1: New findings. J. Pharm. Biomed. Anal., 2019, 172, 395-405.
[http://dx.doi.org/10.1016/j.jpba.2019.05.022] [PMID: 31122801]
[14]
Committee for Medicinal Products for Human Use (CHMP). Guidelines on the limits of genotoxic impurities (CPMP/SWP/5199/02); European Medicines Agency Evaluation of Medicines for Human Use (EMEA): London 2006, 25(10), 1639-1645.
[15]
U.S. Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Guidance for industry: genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft); U.S. Food and Drug Administration: Silver Spring,, 2008.
[16]
Questions and answers on “Information on nitrosamines for marketing authorization holders” [EB/OL]. . Available from: https://www.ema.europa.eu/en/documents/referral/nitrosaminesemea-h-a53-1490-questions-answers-information-nitrosamines-marketingauthorisation_en.pdf (Accessed Jun 25, 2023).
[17]
ICH guideline M7 (R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk [EB/OL].. Available from: https://www.ema.europa.eu/en/documents/scientificguideline/guideline-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential_en.pdf(Accessed Jun 25, 2023).
[18]
Pharmacopoeia Committee of P.R. Pharmacopoeia of People’s Republic of China; China Medical Science and Technology Press: Beijing, 2020.
[19]
Center For Drug Evaluation, National Medical Products Administration. Technical Guidelines for the Study of Nitrosamine Impurities in Chemical Drugs (Trial). Available from: https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200508160101122.html (Accessed Jun 25, 2023).
[20]
International Diabetes Federation. Recommendations For Managing Type 2 Diabetes In Primary Care.. Available from: www.idf.org/managing-type2-diabetes (Accessed Jun 26, 2023).
[21]
International Diabetes Federation. IDF Diabetes Atlas, 9th; . Available from: https://www.diabetesatlas.org (Accessed Jun 26, 2023).
[22]
Statement from Janet Woodcock. M. D, director of FDA’s Center for Drug Evaluation and Research, on impurities found in diabetes drugs outside the U.S [EB/OL].. Available from: https://www.fda.gov/news-events/press-announcements/statementjanet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found (Accessed Jun 27, 2023).
[23]
FDA Updates and Press Announcements on NDMA in Metformin [EB/OL].. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcementsndma-metformin (Accessed Jun 27, 2023).
[24]
Parr, M.K.; Joseph, J.F. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines. J. Pharm. Biomed. Anal., 2019, 164, 536-549.
[http://dx.doi.org/10.1016/j.jpba.2018.11.010] [PMID: 30458387]
[25]
Kee, C.L.; Zeng, Y.; Ge, X.; Lim, J.Q.; Teo Jessie, H.G.; Low, M.Y. Analysis of N ‐nitrosodimethylamine in metformin hydrochloride products by high‐resolution accurate mass gas chromatography mass spectrometry. Rapid Commun. Mass Spectrom., 2023, 37(1), e9414.
[http://dx.doi.org/10.1002/rcm.9414] [PMID: 36239213]
[26]
Fritzsche, M.; Blom, G.; Keitel, J.; Goettsche, A.; Seegel, M.; Leicht, S.; Guessregen, B.; Hickert, S.; Reifenberg, P.; Cimelli, A.; Baranowski, R.; Desmartin, E.; Barrau, E.; Harrison, M.; Bristow, T.; O’Neill, N.; Kirsch, A.; Krueger, P.; Saal, C.; Mouton, B.; Schlingemann, J. NDMA analytics in metformin products: Comparison of methods and pitfalls. Eur. J. Pharm. Sci., 2022, 168, 106026.
[http://dx.doi.org/10.1016/j.ejps.2021.106026] [PMID: 34597792]